From Detection to Decision: Linking Microbiological Diagnostics to the Clinical Management of Carbapenem-Resistant Acinetobacter baumannii Infection

Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a major diagnostic challenge in healthcare-associated infections. Effective management requires clinicians to determine whether a positive result represents active infection, characterize resistance, and identify treatment options. This narrative review examines established and emerging CRAB diagnostic methods, their clinical applications, limitations, and potential to guide antimicrobial therapy. Molecular assays detect selected carbapenem-resistance determinants; however, their target range limits interpretation, and gene detection alone cannot establish the full susceptibility profile. Antimicrobial susceptibility testing (AST) remains essential for assessing isolate-specific activity. Method-dependent uncertainty is especially important for agents such as cefiderocol and colistin. Whole-genome sequencing supports resistance analysis, strain characterization, and outbreak investigation. Metagenomic sequencing, CRISPR-based assays, laboratory automation, and artificial intelligence offer additional capabilities, although their role in routine CRAB management is not established. Distinguishing active infection from colonization remains difficult, particularly with respiratory and wound specimens. Evidence that rapid diagnostic pathways improve outcomes specifically in CRAB infection remains limited; findings from broader bloodstream-infection populations cannot be generalized to every CRAB presentation. Future multicenter studies should validate integrated diagnostic-management pathways and assess their effects on treatment decisions and patient outcomes. Integrating clinical assessment with reliable organism identification and susceptibility testing can support timely, targeted treatment while minimizing unnecessary antimicrobial exposure when CRAB detection represents colonization without evidence of active infection.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-16
DOI
https://doi.org/10.3390/diagnostics16223799
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Detection to Decision: Linking Microbiological Diagnostics to the Clinical Management of Carbapenem-Resistant Acinetobacter baumannii Infection

Ayman Elbehiry, Eman Marzouk, Ihab Mohamed Moussa, Abdulaziz Mohammed Almuzaini et al.
4 links
Diagnostics
Antibiotic Resistance in Bacteria
article

From Detection to Decision: Linking Microbiological Diagnostics to the Clinical Management of Carbapenem-Resistant Acinetobacter baumannii Infection

Ayman Elbehiry, Eman Marzouk, Ihab Mohamed Moussa, Abdulaziz Mohammed Almuzaini, Mai Ibrahem, Khalid Alghamdi, Osama Alrashed, Sulaiman Anagreyyah
article en

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a major diagnostic challenge in healthcare-associated infections. Effective management requires clinicians to determine whether a positive result represents active infection, characterize resistance, and identify treatment options. This narrative review examines established and emerging CRAB diagnostic methods, their clinical applications, limitations, and potential to guide antimicrobial therapy. Molecular assays detect selected carbapenem-resistance determinants; however, their target range limits interpretation, and gene detection alone cannot establish the full susceptibility profile. Antimicrobial susceptibility testing (AST) remains essential for assessing isolate-specific activity. Method-dependent uncertainty is especially important for agents such as cefiderocol and colistin. Whole-genome sequencing supports resistance analysis, strain characterization, and outbreak investigation. Metagenomic sequencing, CRISPR-based assays, laboratory automation, and artificial intelligence offer additional capabilities, although their role in routine CRAB management is not established. Distinguishing active infection from colonization remains difficult, particularly with respiratory and wound specimens. Evidence that rapid diagnostic pathways improve outcomes specifically in CRAB infection remains limited; findings from broader bloodstream-infection populations cannot be generalized to every CRAB presentation. Future multicenter studies should validate integrated diagnostic-management pathways and assess their effects on treatment decisions and patient outcomes. Integrating clinical assessment with reliable organism identification and susceptibility testing can support timely, targeted treatment while minimizing unnecessary antimicrobial exposure when CRAB detection represents colonization without evidence of active infection.

DiagnosticsVol. 16(22)
Qassim University (SA), King Saud University (SA), King Khalid University (SA)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon